Tuesday, July 18, 2017

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Awarded Australian Patent Protecting Cannabis Infused Edibles

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that the Australian Patent Office has granted patent #2015274698, which protects Lexaria’s method of improving absorption, speed of onset and taste of cannabinoid active agents in edible products. The term of the patent is 20 years from June 10, 2015. “We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles utilizing our technology in Australia,” Chris Bunka, CEO of Lexaria, stated in the news release. “This patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will seek additional licensing and product distribution partnering opportunities.” This morning’s announcement follows the award of a similar patent in the United States in October 2016. Lexaria intends to continue developing and solidifying its patent portfolio through the balance of 2017 and 2018.

Additionally, Lexaria this morning announced that it has received $6,250.75 from the exercise of 27,500 stock options previously granted with an exercise price of $0.2273. These options were exercised by a third party who is neither an officer nor a director of the company.

To view the full press release, visit http://dtn.fm/s7zdH

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: